Vigil Neuroscience Insider Sells All Shares as Sanofi Merger Closes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Vigil Neuroscience, Inc. (VIGL) – Form 4, filed 08/05/2025
Director Bruce Booth reports the disposition of all directly and indirectly held equity in connection with the closing of VIGL’s merger with Sanofi. On the effective date, each share of VIGL common stock was converted into the right to receive $8.00 in cash plus one contingent value right (CVR) worth up to $2.00 upon achievement of a clinical milestone.
- Common shares disposed: 5,000 RSUs (direct), 4,808,896 shares (Atlas Venture Fund XII, L.P.), 1,027,978 shares (Atlas Venture Opportunity Fund I, L.P.).
- Stock options disposed: 144,446 options with exercise prices between $2.19 – $3.39 were accelerated, cashed out for the cash-merger spread, and exchanged for CVRs.
- All unvested RSUs and options became fully vested immediately prior to closing.
- Post-transaction, the reporting person holds no beneficial ownership of VIGL securities.
The filing confirms that VIGL is now a wholly owned Sanofi subsidiary and that legacy shareholders and option/RSU holders have received the stated merger consideration.
Positive
- Merger consideration fixed at $8.00 cash plus a $2.00 CVR per share, providing immediate liquidity and potential additional upside to former shareholders.
- All outstanding RSUs and options fully vested and paid out, eliminating overhang from employee equity and simplifying post-merger capital structure.
Negative
- None.
Insights
TL;DR – Filing confirms cash-out of insider’s entire stake following Sanofi acquisition; consideration equals $8 cash + $2 CVR per share.
This Form 4 is purely transactional: it documents the automatic cancellation and cash settlement of Bruce Booth’s equity at closing of Sanofi’s take-out of Vigil Neuroscience. The data show no residual ownership, signaling full completion of the merger. Because the $8 cash leg exceeds every option strike listed, all options were in-the-money and therefore produced immediate value plus CVRs. The disclosure is consistent with standard Section 16 reporting and carries neutral-to-positive implications: investors receive liquidity and upside via CVR; no new risks are introduced.
Insider Trade Summary
10 transactions reported
Mixed
10 txns
Insider
Booth Bruce
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option Award (Right to Buy) | 7,577 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 12,155 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 9,713 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 13,928 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 34,612 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 18,068 | $0.00 | -- |
| Disposition | Stock Option Award (Right to Buy) | 48,393 | $0.00 | -- |
| Disposition | Common Stock | 5,000 | $0.00 | -- |
| Disposition | Common Stock | 4,808,896 | $0.00 | -- |
| Disposition | Common Stock | 1,027,978 | $0.00 | -- |
Holdings After Transaction:
Stock Option Award (Right to Buy) — 0 shares (Direct);
Common Stock — 0 shares (Direct);
Common Stock — 0 shares (Indirect, By Atlas Venture Fund XII, L.P.)
Footnotes (1)
- This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, Sanofi ("Parent"), and Vesper Acquisition Sub Inc., a wholly owned subsidiary of Parent ("Merger Sub"). Pursuant to the terms of the Merger Agreement, on August 5, 2025 (the "Effective Time"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent. At the Effective Time, each share of Issuer Common Stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest (the "Closing Amount") plus (ii) one contingent value right ("CVR"), representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone (together with the Closing Amount, the "Merger Consideration"). Represents Restricted Stock Units ("RSUs"), each of which represented the contingent right to receive one share of the Common Stock. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU that is outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested, and was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such RSU immediately prior to the Effective Time, multiplied by (b) the Closing Amount and (ii) one CVR for each share subject to such RSU. The Reporting Person is a member of Atlas Venture Associates XII, LLC and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon settlement of this award to Atlas Venture Life Science Advisors, LLC. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any. These shares are held directly by Atlas Venture Fund XII, L.P. ("Atlas Venture Fund XII"). The general partner of Atlas Venture Fund XII is Atlas Venture Associates XII, L.P. ("AVA XII LP"). Atlas Venture Associates XII, LLC ("AVA XII LLC") is the general partner of AVA XII LP. The Reporting Person is a member of AVA XII LLC and disclaims beneficial ownership of such securities held by Atlas Venture Fund XII, except to the extent of his pecuniary interest therein, if any. The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. The Reporting Person is a member of AVAO I LLC and disclaims beneficial ownership of such securities held by Atlas Venture Opportunity Fund I, except to the extent of his pecuniary interest therein, if any. Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding as of immediately prior to the Effective Time, to the extent unvested, was accelerated and became fully vested. Each stock option having an exercise price per share that was less than the Closing Amount was cancelled and converted into the right to receive (i) an amount, without interest, equal to the product of (a) the total number of shares subject to such option immediately prior to the Effective Time, multiplied by (b) the excess of (1) the Closing Amount over (2) the exercise price per share under such option and (ii) one CVR for each share subject to such option.
FAQ
What triggered Bruce Booth's Form 4 filing for VIGL?
The filing records share and option dispositions resulting from Vigil Neuroscience’s merger with Sanofi effective 08/05/2025.
Were unvested RSUs and options affected?
Yes. All unvested RSUs and stock options vested immediately before closing and were cancelled for cash and CVRs.
Does the reporting person still own VIGL securities?
No. The Form 4 shows zero beneficial ownership after the merger.
What is the exercise price range for the cancelled options?
Option exercise prices ranged from $2.19 to $3.39, all below the $8.00 cash merger price.